Publications by authors named "Anne Mette Dybro"
Article Synopsis
- The study aimed to evaluate the effects of trimetazidine, an antianginal medication, on heart function in patients with wild-type transthyretin cardiac amyloidosis (ATTRwt).
- Twenty-two participants were enrolled in a randomized, double-blind trial, comparing the effects of trimetazidine to a placebo over four weeks, measuring various cardiovascular and mitochondrial functions.
- The results showed no significant improvements in key cardiac measures, such as pulmonary artery wedge pressure or mitochondrial function, indicating that trimetazidine did not provide benefits to patients with ATTRwt compared to the placebo.
Background: Truncating variants in titin (TTNtv) are the most common cause of dilated cardiomyopathy (DCM). We evaluated the genotype-phenotype correlation in TTNtv-DCM, with a special focus on long-term outcomes, arrhythmias, response to treatment and sex-related presentation.
Methods: Data on patient characteristics and outcomes were collected retrospectively from electronic health records of patients genotyped at two Danish heart transplantation centres.
A 47-year-old woman had been treated with high-dose simvastatin for several years. After systemic treatment with the antifungal agent itraconazole, she developed muscle pain and highly elevated levels of creatine kinase and myoglobin. Muscle biopsy was compatible with statin-associated rhabdomyolysis, probably caused by a drug-drug interaction between simvastatin and itraconazole.
View Article and Find Full Text PDF